{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:12:57Z","timestamp":1785795177526,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T00:00:00Z","timestamp":1403136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms4897","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T06:47:09Z","timestamp":1403160429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators"],"prefix":"10.1038","volume":"5","author":[{"given":"Nadine J.","family":"Ortner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.F.","family":"Vandael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mauersberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning J.","family":"Draheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronel","family":"Tuluc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Striessnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,19]]},"reference":[{"key":"BFncomms4897_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1124\/pr.57.4.5","volume":"57","author":"WA Catterall","year":"2005","unstructured":"Catterall, W. A., Perez-Reyes, E., Snutch, T. P. & Striessnig, J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57, 411\u2013425 (2005).","journal-title":"Pharmacol. Rev."},{"key":"BFncomms4897_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/chan.2.4.5847","volume":"2","author":"J Striessnig","year":"2008","unstructured":"Striessnig, J. & Koschak, A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels (Austin) 2, 233\u2013251 (2008).","journal-title":"Channels (Austin)"},{"key":"BFncomms4897_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wmts.102","volume":"3","author":"J Striessnig","year":"2014","unstructured":"Striessnig, J., Pinggera, A., Kaur, G., Bock, G. & Tuluc, P. L-type calcium channels in heart and brain. Wiley Interdiscip. Rev. Membr. Transp. Signal. 3, 15\u201338 (2014).","journal-title":"Wiley Interdiscip. Rev. Membr. Transp. Signal."},{"key":"BFncomms4897_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1152\/physrev.00016.2013","volume":"94","author":"F Hofmann","year":"2014","unstructured":"Hofmann, F., Flockerzi, V., Kahl, S. & Wegener, J. W. L-type Cav1.2 calcium channels: from in vitro findings to in vivo function. Physiol. Rev. 94, 303\u2013326 (2014).","journal-title":"Physiol. Rev."},{"key":"BFncomms4897_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0165-6147(98)01171-7","volume":"19","author":"J Striessnig","year":"1998","unstructured":"Striessnig, J. et al. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci. 19, 108\u2013115 (1998).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFncomms4897_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1523\/JNEUROSCI.3327-04.2005","volume":"25","author":"PA Olson","year":"2005","unstructured":"Olson, P. A. et al. G-protein-coupled receptor modulation of striatal Cav1.3 L-type calcium channels is dependent on a Shank-binding domain. J. Neurosci. 25, 1050\u20131062 (2005).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.nlm.2009.06.012","volume":"92","author":"BC McKinney","year":"2009","unstructured":"McKinney, B. C., Sze, W., Lee, B. & Murphy, G. G. Impaired long-term potentiation and enhanced neuronal excitability in the amygdala of Cav1.3 knockout mice. Neurobiol. Learn. Mem. 92, 519\u2013528 (2009).","journal-title":"Neurobiol. Learn. Mem."},{"key":"BFncomms4897_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1172\/JCI20208","volume":"113","author":"MJ Sinnegger-Brauns","year":"2004","unstructured":"Sinnegger-Brauns, M. J. et al. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type calcium channels. J. Clin. Invest. 113, 1430\u20131439 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFncomms4897_CR9","doi-asserted-by":"publisher","first-page":"42736","DOI":"10.1074\/jbc.M111.269951","volume":"286","author":"G Bock","year":"2011","unstructured":"Bock, G. et al. Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type Ca2+ channels. J. Biol. Chem. 286, 42736\u201342748 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFncomms4897_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1523\/JNEUROSCI.4961-09.2010","volume":"30","author":"A Marcantoni","year":"2010","unstructured":"Marcantoni, A. et al. Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J. Neurosci. 30, 491\u2013504 (2010).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR11","doi-asserted-by":"publisher","first-page":"15414","DOI":"10.1523\/JNEUROSCI.4742-09.2009","volume":"29","author":"I Putzier","year":"2009","unstructured":"Putzier, I., Kullmann, P. H., Horn, J. P. & Levitan, E. S. Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 29, 15414\u201315419 (2009).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR12","doi-asserted-by":"publisher","first-page":"11011","DOI":"10.1523\/JNEUROSCI.2519-09.2009","volume":"29","author":"JN Guzman","year":"2009","unstructured":"Guzman, J. N., Sanchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011\u201311019 (2009).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1089\/ars.2010.3521","volume":"14","author":"DJ Surmeier","year":"2011","unstructured":"Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J. & Goldberg, J. A. The origins of oxidant stress in Parkinson\u2019s disease and therapeutic strategies. Antioxid. Redox. Signal. 14, 1289\u20131301 (2011).","journal-title":"Antioxid. Redox. Signal."},{"key":"BFncomms4897_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","volume":"43","author":"E Ilijic","year":"2011","unstructured":"Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson\u2019s disease. Neurobiol. Dis. 43, 364\u2013371 (2011).","journal-title":"Neurobiol. Dis."},{"key":"BFncomms4897_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","volume":"70","author":"C Becker","year":"2008","unstructured":"Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438\u20131444 (2008).","journal-title":"Neurology"},{"key":"BFncomms4897_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","volume":"67","author":"B Ritz","year":"2010","unstructured":"Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600\u2013606 (2010).","journal-title":"Ann. Neurol."},{"key":"BFncomms4897_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ncomms2149","volume":"3","author":"S Kang","year":"2012","unstructured":"Kang, S. et al. Cav1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease. Nat. Commun. 3, 1146 (2012).","journal-title":"Nat. Commun."},{"key":"BFncomms4897_CR18","doi-asserted-by":"publisher","first-page":"22100","DOI":"10.1074\/jbc.M101469200","volume":"276","author":"A Koschak","year":"2001","unstructured":"Koschak, A. et al. \u03b11D (Cav1.3) subunits can form L-type calcium channels activating at negative voltages. J. Biol. Chem. 276, 22100\u201322106 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFncomms4897_CR19","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1523\/JNEUROSCI.21-16-05944.2001","volume":"21","author":"W Xu","year":"2001","unstructured":"Xu, W. & Lipscombe, D. Neuronal Cav1.3\u03b11 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci. 21, 5944\u20135951 (2001).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan, C. S. et al. \u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease. Nature 447, 1081\u20131086 (2007).","journal-title":"Nature"},{"key":"BFncomms4897_CR21","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1021\/jm4005048","volume":"56","author":"S Kang","year":"2013","unstructured":"Kang, S. et al. Structure-activity relationship of N,N\u2019-disubstituted pyrimidinetriones as Cav1.3 calcium channel-selective antagonists for Parkinson\u2019s disease. J. Med. Chem. 56, 4786\u20134797 (2013).","journal-title":"J. Med. Chem."},{"key":"BFncomms4897_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/nature06529","volume":"451","author":"IE Dick","year":"2008","unstructured":"Dick, I. E. et al. A modular switch for spatial Ca2+ selectivity in the calmodulin regulation of Cav channels. Nature 451, 830\u2013834 (2008).","journal-title":"Nature"},{"key":"BFncomms4897_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1529\/biophysj.104.051714","volume":"88","author":"SI McDonough","year":"2005","unstructured":"McDonough, S. I., Mori, Y. & Bean, B. P. FPL 64176 modification of Cav1.2 L-type calcium channels: dissociation of effects on ionic current and gating current. Biophys. J. 88, 211\u2013223 (2005).","journal-title":"Biophys. J."},{"key":"BFncomms4897_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s002100000219","volume":"361","author":"JS Fan","year":"2000","unstructured":"Fan, J. S., Yuan, Y. & Palade, P. Kinetic effects of FPL 64176 on L-type Ca2+ channels in cardiac myocytes. Naunyn. Schmiedebergs. Arch. Pharmacol. 361, 465\u2013476 (2000).","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"BFncomms4897_CR25","doi-asserted-by":"publisher","first-page":"16345","DOI":"10.1523\/JNEUROSCI.3715-12.2012","volume":"32","author":"DH Vandael","year":"2012","unstructured":"Vandael, D. H., Zuccotti, A., Striessnig, J. & Carbone, E. Cav1.3-driven SK channel activation regulates pacemaking and spike frequency adaptation in mouse chromaffin cells. J. Neurosci. 32, 16345\u201316359 (2012).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4161\/chan.5.3.15271","volume":"5","author":"S Mahapatra","year":"2011","unstructured":"Mahapatra, S., Marcantoni, A., Vandael, D. H., Striessnig, J. & Carbone, E. Are Cav1.3 pacemaker channels in chromaffin cells? Possible bias from resting cell conditions and DHP blockers usage. Channels (Austin)5, 219\u2013224 (2011).","journal-title":"Channels"},{"key":"BFncomms4897_CR27","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","volume":"21","author":"S Kang","year":"2013","unstructured":"Kang, S. et al. Antagonism of L-type Ca2+ channels Cav1.3 and Cav1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorg. Med. Chem. 21, 4365\u20134373 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"BFncomms4897_CR28","doi-asserted-by":"publisher","first-page":"9523","DOI":"10.1073\/pnas.90.20.9523","volume":"90","author":"H Glossmann","year":"1993","unstructured":"Glossmann, H. et al. A light stabilizer (Tinuvin 770) that elutes from polypropylene plastic tubes is a potent L-type Ca2+-channel blocker. Proc. Natl Acad. Sci. USA 90, 9523\u20139527 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4897_CR29","doi-asserted-by":"publisher","first-page":"10677","DOI":"10.1523\/JNEUROSCI.3236-06.2006","volume":"26","author":"PS Yang","year":"2006","unstructured":"Yang, P. S. et al. Switching of calcium-dependent inactivation of Cav1.3 channels by calcium binding proteins of auditory hair cells. J. Neurosci. 26, 10677\u201310689 (2006).","journal-title":"J. Neurosci."},{"key":"BFncomms4897_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1113\/jphysiol.2006.111799","volume":"576","author":"JT Hulme","year":"2006","unstructured":"Hulme, J. T., Yarov-Yarovoy, V., Lin, T. W., Scheuer, T. & Catterall, W. A. Autoinhibitory control of the Cav1.2 channel by its proteolytically processed distal C-terminal domain. J. Physiol. 576, 87\u2013102 (2006).","journal-title":"J. Physiol."},{"key":"BFncomms4897_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cell.2006.10.017","volume":"127","author":"N Gomez-Ospina","year":"2006","unstructured":"Gomez-Ospina, N., Tsuruta, F., Barreto-Chang, O., Hu, L. & Dolmetsch, R. The C terminus of the L-type voltage-gated calcium channel Cav1.2 encodes a transcription factor. Cell 127, 591\u2013606 (2006).","journal-title":"Cell"},{"key":"BFncomms4897_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0028-3908(03)00153-9","volume":"45","author":"L Liu","year":"2003","unstructured":"Liu, L., Gonzalez, P. K., Barrett, C. F. & Rittenhouse, A. R. The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology 45, 281\u2013292 (2003).","journal-title":"Neuropharmacology"},{"key":"BFncomms4897_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/jpet.112.192609","volume":"341","author":"J Kang","year":"2012","unstructured":"Kang, J., Chen, X. L., Ji, J., Lei, Q. & Rampe, D. Ca2+ channel activators reveal differential L-type Ca2+ channel pharmacology between native and stem cell-derived cardiomyocytes. J. Pharmacol. Exp. Ther. 341, 510\u2013517 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFncomms4897_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1152\/jn.2001.85.2.816","volume":"85","author":"DC Bell","year":"2001","unstructured":"Bell, D. C. et al. Biophysical properties, pharmacology, and modulation of human, neuronal L-type alpha1D (Cav1.3) voltage-dependent calcium currents. J. Neurophysiol. 85, 816\u2013827 (2001).","journal-title":"J. Neurophysiol."},{"key":"BFncomms4897_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/mp.2009.49","volume":"15","author":"EK Green","year":"2010","unstructured":"Green, E. K. et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry 15, 1016\u20131022 (2010).","journal-title":"Mol. Psychiatry"},{"key":"BFncomms4897_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4161\/chan.21002","volume":"6","author":"A Lieb","year":"2012","unstructured":"Lieb, A., Scharinger, A., Sartori, S., Sinnegger-Brauns, M. J. & Striessnig, J. Structural determinants of Cav1.3 L-type calcium channel gating. Channels (Austin) 6, 197\u2013205 (2012).","journal-title":"Channels (Austin)"},{"key":"BFncomms4897_CR37","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1073\/pnas.0409885102","volume":"102","author":"JT Hulme","year":"2005","unstructured":"Hulme, J. T. et al. Sites of proteolytic processing and noncovalent association of the distal C-terminal domain of Cav1.1 channels in skeletal muscle. Proc. Natl Acad. Sci. USA 102, 5274\u20135279 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4897_CR38","doi-asserted-by":"publisher","first-page":"16574","DOI":"10.1073\/pnas.0607294103","volume":"103","author":"JT Hulme","year":"2006","unstructured":"Hulme, J. T., Westenbroek, R. E., Scheuer, T. & Catterall, W. A. Phosphorylation of serine 1928 in the distal C-terminal domain of cardiac Cav1.2 channels during beta1-adrenergic regulation. Proc. Natl Acad. Sci. USA 103, 16574\u201316579 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4897_CR39","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1016\/j.bmc.2010.03.038","volume":"18","author":"CC Chang","year":"2010","unstructured":"Chang, C. C. et al. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg. Med. Chem. 18, 3147\u20133158 (2010).","journal-title":"Bioorg. Med. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncomms4897.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncomms4897","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms4897.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T17:55:01Z","timestamp":1716832501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms4897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,9,22]]}},"alternative-id":["BFncomms4897"],"URL":"https:\/\/doi.org\/10.1038\/ncomms4897","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718457476.793496473","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,19]]},"assertion":[{"value":"26 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HJD is an employee of Boehringer Ingelheim Pharma GmbH & Co KG. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3897"}}